drugset / Trial / NCT01519661
Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study assessed the long term safety data for the use of tobramycin inhalation powder in patients suffering from cystic fibrosis who have a chronic pulmonary infection with Pseudomonas aeruginosa.
Timeline
- Start
- 2012-01
- Primary completion
- 2014-01
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tobramycin | Small molecule | 112 mg | Inhaled |